While current influenza vaccines primarily target the variable hemagglutinin protein, the slower-evolving neuraminidase presents a promising target for the development of new vaccines providing broader protection.

Scientists at Institut Pasteur have gained new insights into how some people control HIV-1 replication after interruption of antiretroviral treatment (ART). The investigators found a fingerprint involved in long-term viral remission.

Research of the neuroimmune mechanisms involved in stress-related fear revealed how astrocytes interact with neurons in the amygdala. The study, led by Harvard scientists, also unveiled that this interaction recruited monocytes to the meninges during chronic stress and showed how psychedelic compounds reversed monocyte accumulation in the meninges and reduced fear behavior.

Granite Bio AG has emerged from stealth with $100 million in series A and B funding and a focus on developing first-in-class antibodies that target the root causes of a variety of inflammatory, autoimmune and fibrotic conditions.

Repertoire Immune Medicines Inc. has entered into a collaboration and license agreement with Genentech Inc., a member of the Roche Group, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. Repertoire will use its Decode platform, which maps the immune synapse, to discover novel therapeutic targets.

Writing in Scientific Reports, researchers from the Stiftung Tieraerztliche Hochschule Hannover and collaborators present the design and evaluation of an artificial poly-epitope sequence comprising 20 potentially immunogenic conserved influenza A virus CD8+ T cell epitopes as a new vaccine candidate.

CC chemokine receptor 6 (CCR6) is a G-protein coupled receptor involved in guiding immune cells through the body and the hallmark receptor for T helper 17 (Th17) cells, and is also expressed in other immune cell populations, such as B cells and innate lymphoid cells, among others.

After more than three years of discussion, the World Health Organization’s Intergovernmental Negotiating Body (INB) has agreed on a proposal to prevent, prepare and respond to a pandemic. The plan is born, the INB proposal said, out of inequities around the world that slowed timely and equitable access to health products to respond to the COVID-19 pandemic.